60 Degrees Pharmaceuticals Will Release Trial Data
The company will share interim clinical results on October 6, 2026, for a potential babesiosis treatment.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize finding treatments for rare diseases?
60 Degrees Pharmaceuticals is set to release interim clinical trial data for its investigation into the use of tafenoquine for severe babesiosis on October 6, 2026. This research, identified as NCT06207370, aims to address the current lack of an FDA-approved treatment or vaccine for the tick-borne disease.
Why it matters
The company aims to close a significant gap in medical care for treatment-refractory babesiosis, a condition currently lacking targeted therapeutic options. This development seeks to leverage an existing drug platform for a new indication as the firm navigates financial sustainability concerns.
The study evaluates the efficacy of tafenoquine, an aminoquinoline currently FDA-approved under the brand name ARAKODA for malaria prophylaxis, against severe cases of babesiosis. The clinical study ID is NCT06207370.
The players
60 Degrees Pharmaceuticals
A Washington, D.C.-based biotech firm focused on developing therapeutic medicines for neglected and vector-borne diseases.
Peter Krause
A medical professional and subject matter expert scheduled to present findings during the upcoming investor webinar.
Edouard Vannier
A researcher and subject matter expert participating in the company's interim data presentation.
The details
Babesiosis is a parasitic infection transmitted by ticks that typically requires antibiotic intervention, yet no specific vaccine or dedicated treatment is currently approved by the FDA. Tafenoquine — an 8-aminoquinoline compound known for its anti-malarial properties — is being studied to determine if it can offer an alternative mechanism for patients with severe, treatment-refractory cases. The study's interim findings will be detailed by clinical experts during an upcoming investor webinar.
Timeline
2010: 60 Degrees Pharmaceuticals was founded.
2018: The FDA approved tafenoquine for malaria prevention.
March 30, 2026: The company filed its Annual Report on Form 10-K with the SEC.
October 6, 2026: The company will release interim study data and host an investor webinar at 11:00 a.m. ET.
The Tech Race
This trial follows the regulatory precedent established by the FDA-approved malaria prevention pathway for tafenoquine. The company is now attempting to extend the utility of that established therapeutic into the treatment of a distinct, currently unaddressed tick-borne infection.
Patients and clinicians currently lack approved therapeutic options for babesiosis, and this study represents an early stage of clinical investigation rather than a commercially available drug. Any potential clinical application remains subject to the results of study NCT06207370 and future regulatory review.
The takeaway
The firm is attempting to repurpose an existing drug for a disease that currently lacks any approved pharmaceutical solution. Stakeholders should monitor the interim data on October 6, 2026, alongside the company's financial disclosures regarding its going-concern status.
Further reading
For broader context on current clinical research, explore the Biotech section.
Live Poll
Do you trust pharmaceutical companies to prioritize finding treatments for rare diseases?
